Abstract | BACKGROUND: AIM: PATIENTS AND METHOD: Sixteen women (group 1) with peripheral hirsutism (defined as those with normal androgens levels, normal menstrual cycles and ovulation) and 24 women (group 2) with glucocorticoid sensitive hyperandrogenic hirsutism were studied. Group 1 was treated with spironolactone 50 mg hid and group 2 with same spironolactone dose plus dexamethasone 0.5 mg at 23 h during one month and 0.25 mg thereafter. Patients were followed during one year. RESULTS: After one year of treatment, a 54% reduction in Moncada hirsutism escore was observed in group 1 and 52% reduction in group 2. Observed secondary effects of spironolactone were increases in diuresis, fatigability, acne aggravation and seborrhea in two patients. Two additional patients had spotting. No secondary effect attributable to glucocorticoid use were observed. CONCLUSIONS:
Spironolactone is effective and safe in the treatment of hirsutism. Androgenic supression did no increases its effectiveness, underscoring the peripheral anti androgenic activity os spironolactone.
|
Authors | E Devoto, L Aravena, R Ríos |
Journal | Revista medica de Chile
(Rev Med Chil)
Vol. 128
Issue 8
Pg. 868-75
(Aug 2000)
ISSN: 0034-9887 [Print] Chile |
Vernacular Title | Tratamiento del hirsutismo con espironolactona y con espironolactona más dexametasona. |
PMID | 11129548
(Publication Type: Clinical Trial, Controlled Clinical Trial, English Abstract, Journal Article)
|
Chemical References |
- Glucocorticoids
- Mineralocorticoid Receptor Antagonists
- Spironolactone
- Dexamethasone
|
Topics |
- Adolescent
- Adult
- Dexamethasone
(therapeutic use)
- Drug Therapy, Combination
- Female
- Follow-Up Studies
- Glucocorticoids
(therapeutic use)
- Hirsutism
(blood, drug therapy)
- Humans
- Mineralocorticoid Receptor Antagonists
(therapeutic use)
- Spironolactone
(therapeutic use)
- Treatment Outcome
|